Comparison of Nebivolol and Bisoprolol for Cardiovascular Mortality in Hypertensive Patients

Ratan Kumar; Kheraj Mal; Jamila Begum; Faizan Shaukat

doi:10.7759/cureus.6453

Comparison of Nebivolol and Bisoprolol for Cardiovascular Mortality in Hypertensive Patients

Cureus. 2019 Dec 23;11(12):e6453. doi: 10.7759/cureus.6453.

Authors

Ratan Kumar¹, Kheraj Mal², Jamila Begum³, Faizan Shaukat⁴

Affiliations

¹ Cardiology, Khairpur Medical College, Nawabshah, PAK.
² Cardiology, National Institute of Cardiovascular Diseases, Sukkur, PAK.
³ Internal Medicine, Dow University of Health Sciences, Karachi, PAK.
⁴ Internal Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK.

Abstract

Introduction Beta-blockers again are now considered as first-line therapy for various cardiovascular diseases. In this study, we compare the cardiovascular event between two beta-blocker, i.e. Nebivolol and Bisoprolol. Materials and Methods It is a two-arm open-label randomized prospective study that was conducted from 1^st Jan 2016 to 30^th July 2019 in tertiary care hospital, Nawabshah. One thousand and fifty-six (n=1056) hypertensive patients were enrolled after informed consent, which were randomized into two equal groups. Patients were followed up for one year. Results Comparison between Nebivolol and Bisoprolol showed that all-cause mortality (9.8% vs 11.48%), cardiovascular mortality (5.4% vs 7.0%), all-cause hospitalization (14.4% vs 16.3%), and cardiovascular hospitalization (9.8% vs 12.09%) was numerically lower in nebivolol but the difference was not statistically significant. Conclusion Further large scale multicentric trials with a longer follow up period are needed to compare various beta-blockers for cardiovascular event.

Keywords: bisoprolol; cardiology; nebivolol.